Drug Profile
Research programme: doxorubicin nanoparticles - SIOGEN Biotech
Alternative Names: SioONCOLatest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator Siogen Biotech
- Developer SIOGEN Biotech
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Malaysia
- 06 May 2010 Early research in Cancer in Malaysia (unspecified route)